Search results
Showing 951 to 1000 of 1515 results for patients and public
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
Advocacy services for adults with health and social care needs (NG227)
This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
This quality standard covers assessing, diagnosing and managing head and neck cancer, including cancer of the upper aerodigestive tract in people aged 16 or over. It describes high-quality care in priority areas for improvement.
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Awaiting development Reference number: GID-TA11218 Expected publication date: TBC
Awaiting development Reference number: GID-TA11500 Expected publication date: TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]
Awaiting development Reference number: GID-TA11458 Expected publication date: TBC
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Awaiting development Reference number: GID-TA11087 Expected publication date: TBC
Awaiting development Reference number: GID-TA11758 Expected publication date: TBC
Awaiting development Reference number: GID-TA11639 Expected publication date: TBC
Awaiting development Reference number: GID-TA11659 Expected publication date: 13 May 2027
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]
Awaiting development Reference number: GID-TA11855 Expected publication date: TBC
Awaiting development Reference number: GID-TA11624 Expected publication date: TBC
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
People can comment on our guidance at specific stages in its development.
People can comment on our guidance at specific stages in its development.
This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care.
In development Reference number: GID-TA11584 Expected publication date: 08 December 2027
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Awaiting development Reference number: GID-TA10961 Expected publication date: TBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]
In development Reference number: GID-TA11071 Expected publication date: TBC
In development Reference number: GID-TA11422 Expected publication date: TBC
Awaiting development Reference number: GID-TA11538 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 20 February 2026.
In development Reference number: GID-TA11694 Expected publication date: TBC
In development Reference number: GID-TA11130 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 18 February 2026.
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.
Stretta System for gastro-oesophageal reflux disease (MIB74)
NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease
Cardiovascular disease prevention: blood pressure measurement every 5 years (IND112)
This indicator covers the percentage of patients aged 40 years and over with a blood pressure measurement recorded in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM61
Evidence-based recommendations on peginterferon alfa (Pegasys; ViraferonPeg) and ribavirin (Copegus) for treating chronic hepatitis C in children and young people.
Evidence-based recommendations on photochemical corneal cross linkage using riboflavin and ultraviolet A for keratoconus. This involves using special eye drops and exposing the eye ultraviolet light, with the aim to strengthen the cornea.
Our framework agreement allows UK NHS, health and social care organisations to buy knowledge resources that support practice, learning and development.
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]
In development Reference number: GID-TA11154 Expected publication date: TBC
PillCam COLON 2 for investigation of the colon through direct visualisation
In development Reference number: GID-DG10083 Expected publication date: TBC
In development Reference number: GID-TA11162 Expected publication date: 28 July 2027
Monofocal intraocular lenses for cataract surgery (provisional title)
In development Reference number: GID-HTE10090 Expected publication date: TBC
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor
In development Reference number: GID-IPG10441 Expected publication date: TBC
We are listening to your views on this Interventional procedures guidance. Comments close 11 February 2026.
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (HTG611)
Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules.
Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)
NICE has developed a medtech innovation briefing (MIB) on the Xpert Carba-R to identify people carrying carbapenemase-producing organisms
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]
In development Reference number: GID-TA11410 Expected publication date: TBC
In development Reference number: GID-TA11497 Expected publication date: TBC
In development Reference number: GID-TA11336 Expected publication date: TBC
Awaiting development Reference number: GID-TA11343 Expected publication date: TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
In development Reference number: GID-TA11501 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.
Artificial intelligence (AI) technologies to help detect prostate cancer on multiparametric (mp) MRI
In development Reference number: GID-HTE10089 Expected publication date: TBC
Denecimig (Mim8) for preventing bleeding episodes in haemophilia A in people of any age [ID6400]
Awaiting development Reference number: GID-TA11509 Expected publication date: TBC
Artificial intelligence software to help detect and characterise colorectal polyps
In development Reference number: GID-DG10118 Expected publication date: TBC